uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery
Department of Medicine, Mälar Hospital, Eskilstuna, Sweden .
2011 (English)In: Drug Safety, ISSN 0114-5916, Vol. 34, no 6, 449-463 p.Article in journal (Refereed) Published
Abstract [en]

Dabigatran etexilate is a novel orally administered anticoagulant that exerts its action through reversible direct thrombin inhibition. This anticoagulant has been approved for prophylaxis against venous thromboembolism (VTE) after hip or knee arthroplasty, and in a few countries also for atrial fibrillation. This article reviews the efficacy and safety of dabigatran for the prophylaxis of VTE-indication compared with data on the most common current regimen with low-molecular-weight heparin (LMWH), specifically enoxaparin. Alternative prophylactic agents are also discussed. The results regarding efficacy and safety are very similar for dabigatran and LMWH. Bleeding and gastrointestinal reactions are the most frequently reported adverse events with a comparable incidence on LMWH and are probably the result of surgery and anaesthaesia. No adverse event that is specific for dabigatran has been observed in these studies, although dyspepsia has been reported as significantly more frequent than warfarin in long-term studies on other indications. The fact that dabigatran has no antidote has so far not been a problem in patients undergoing orthopaedic surgery. The use of the lower dose of dabigatran (150 mg) appears beneficial to reduce the risk of bleeding in patients over 75 years of age and in those with moderate renal impairment to avoid drug accumulation. The convenience of oral administration is an advantage for dabigatran over LMWH, particularly for extended prophylaxis up to 1 month after surgery. In conclusion, the benefit-risk profile of dabigatran is favourable for use as prophylaxis against VTE after major orthopaedic surgery with its convenient oral administration without need for laboratory monitoring and a low risk of bleeding or other adverse events.

Place, publisher, year, edition, pages
2011. Vol. 34, no 6, 449-463 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-197775DOI: 10.2165/11587290-000000000-00000PubMedID: 21585219OAI: oai:DiVA.org:uu-197775DiVA: diva2:614101
Available from: 2013-04-03 Created: 2013-04-03 Last updated: 2013-04-03Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
In the same journal
Drug Safety
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 146 hits
ReferencesLink to record
Permanent link

Direct link